Neurocrine Biosciences Inc (NBIX NASDAQ) stock market data APIs
$142.0444
-3.02(-2.1%)
as of October 31, 2025
Try our APIs with
free plan!
Neurocrine Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Prev. Close
142.0444
Open
139.0272
High
143.3695
Low
138.0122
52 wk Range
84.23-154.61
Market Cap
14 279 M
P/E Ratio
34.0976
Shares Outstanding
99 706 K
Revenue
2 683 M
EPS
2.17
Beta
0.212
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurocrine Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurocrine Biosciences Inc data using free add-ons & libraries
Get Neurocrine Biosciences Inc Fundamental Data
Neurocrine Biosciences Inc Fundamental data includes:
- Net Revenue: 2 683 M
- EBITDA: 570 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 2.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurocrine Biosciences Inc News
New
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments
Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ...
This article first appeared on GuruFocus. Net Product Sales: $790 million, reflecting 28% year-over-year growth. CRENESSITY Sales: Grew from $53 million in Q2 to $98 million in Q3. INGREZZA Sales: Ne...
Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives
Neurocrine Biosciences (NBIX) is projecting robust growth, with annual revenue set to rise 10.9%, outpacing the broader US market’s forecast of 10.2%. Earnings growth is especially notable, with exp...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
